EE344 Cost-Effectiveness of a Novel Treatment for Stroke Prevention in Patients with Atrial Fibrillation: Results from an Early Economic Analysis

For many patients with atrial fibrillation (AF) at moderate-to-high risk of stroke, clinically significant bleeding from anticoagulants remains a concern, leading to withholding or discontinuation of anticoagulation. Patients who are unsuitable for or inadequately treated with currently available anticoagulants remain at higher risk for stroke and systemic embolism. This early economic analysis explored the potential cost-effectiveness of a hypothetical new therapy that reduces the risk of stroke in patients with AF who are unsuitable for treatment with currently available anticoagulants.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research